Last reviewed · How we verify
Radium-223 and enzalutamide — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Radium-223 and enzalutamide (Radium-223 and enzalutamide) — Cancer Trials Ireland.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Radium-223 and enzalutamide TARGET | Radium-223 and enzalutamide | Cancer Trials Ireland | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Radium-223 and enzalutamide CI watch — RSS
- Radium-223 and enzalutamide CI watch — Atom
- Radium-223 and enzalutamide CI watch — JSON
- Radium-223 and enzalutamide alone — RSS
Cite this brief
Drug Landscape (2026). Radium-223 and enzalutamide — Competitive Intelligence Brief. https://druglandscape.com/ci/radium-223-and-enzalutamide. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab